Travere Therapeutics, CSL Vifor announce EC approves FILSPARI

Travere Therapeutics and CSL Vifor announced that the European Commission, EC, has granted conditional marketing authorization, CMA, for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion greater than or equal to1.0 g/day. The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway. “As the first and only non-immunosuppressive therapy approved for IgAN, we believe FILSPARI offers clinicians the potential for a new foundational treatment for this rare kidney disease, replacing RAAS inhibition,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “With this approval and the commercial strength and expertise of our partner, CSL Vifor, we look forward to people living with IgAN in Europe gaining access to this important medicine.”